Hyperuricemia Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031F

Secondary is the fastest growing sector, North America is the largest market

The global hyperuricemia market, which includes urate-lowering therapeutics and diagnostic tools for managing elevated serum uric acid, is projected to expand from USD 4.78 billion in 2025 to USD 7.13 billion by 2031, achieving a compound annual growth rate of 6.89%. This growth is primarily fueled by the increasing worldwide prevalence of gouty arthritis and the expanding elderly population, who are more susceptible to metabolic disorders. Furthermore, widespread lifestyle changes, such as diets rich in purines and rising obesity rates, are significantly enlarging the patient pool that requires long-term pharmacological intervention, thus boosting demand for xanthine oxidase inhibitors and uricosuric agents.

However, market expansion is frequently impeded by poor patient adherence to chronic therapy and the potential toxicity associated with existing first-line medications. For instance, the American College of Rheumatology reported in 2025 that the national average disability-adjusted life year rate for gout in the United States increased by 93.7% over the previous two decades, underscoring a growing burden that current management strategies have not fully alleviated. This deficiency in effective long-term care presents a significant challenge to the industry, as safety concerns and compliance issues restrict the consistent adoption of available treatments.

Market Drivers

The market's expansion is primarily driven by the rising global incidence of gout and asymptomatic hyperuricemia, fueled by an aging global population and evolving dietary patterns. As life expectancy increases, the geriatric population expands, leading to a higher frequency of crystal deposition diseases linked to reduced renal urate excretion. This demographic trend is compounded by the widespread adoption of high-purine diets and sedentary lifestyles, which accelerate metabolic dysfunction and broaden the patient pool requiring pharmacological intervention.

A study published in PubMed Central in June 2025, for example, projects that the age-standardized prevalence rate of gout among older adults will rise to 3,628.85 per 100,000 population by 2050, confirming a sustained demand for effective management solutions. Concurrently, the escalating burden of chronic kidney disease (CKD) and metabolic disorders amplifies the necessity for hyperuricemia management, as elevated uric acid acts as both a complication and a potential progression factor for renal impairment.

This urgency compels healthcare providers to prioritize aggressive urate monitoring and intervention in nephrology settings to prevent further kidney deterioration and manage cardiovascular risks. Scientific Reports, in November 2025, highlighted this critical overlap, revealing that 65.6% of non-dialysis chronic kidney disease patients presented with hyperuricemia. The commercial scale of this high-need segment is evidenced by Amgen's report in February 2025, stating that its targeted gout therapy, KRYSTEXXA, generated $1.2 billion in sales during 2024, demonstrating substantial market value in addressing severe and refractory cases.

Market Challenges

A primary impediment to the global hyperuricemia market's growth is the pervasive issue of poor patient adherence to chronic therapy, compounded by safety concerns associated with first-line medications. Despite an expanding potential patient base, the market's actual growth is significantly hindered because many individuals prematurely discontinue treatment. This high discontinuation rate often arises from the asymptomatic nature of hyperuricemia during inter-critical periods, which leads patients to underestimate the ongoing need for daily pharmacological intervention.

Moreover, fears of toxicity, such as severe cutaneous reactions or cardiovascular risks linked to standard xanthine oxidase inhibitors, cause hesitation among both prescribers and patients, thereby limiting the volume of long-term prescriptions. This widespread lack of compliance directly impacts market performance by reducing prescription refills and diminishing the real-world efficacy of therapeutic agents.

When treatment protocols are not sustained, patient outcomes stagnate, which prevents the widespread adoption of higher-value therapies. According to the American College of Rheumatology, 2025 survey data indicated that adherence to recommended dosing standards for urate-lowering therapy remains suboptimal, with less than 50% of treatment regimens fully aligning with the guidelines necessary to maintain target serum urate levels. This gap in effective utilization ensures that a substantial segment of the addressable market remains under-monetized, preventing the industry from fully capitalizing on the rising prevalence of the disease.

Market Trends

The treatment landscape is undergoing a significant transformation with the rapid emergence of novel selective URAT1 inhibitors, which are designed to address the efficacy limitations of existing xanthine oxidase inhibitors. Pharmaceutical developers are increasingly prioritizing high-potency uricosuric agents that directly target renal transporters to enhance uric acid excretion, offering a viable alternative for patients who fail to achieve target serum levels with standard oral therapies. This clinical shift is exemplified by the advancement of next-generation candidates engineered to maximize efficacy while minimizing renal toxicity.

For instance, FierceBiotech reported in September 2025 that Atom Therapeutics' novel URAT1 inhibitor, ABP-671, achieved an impressive 91% response rate in reducing tophus diameter by week 28 in a pivotal Phase 2b/3 clinical trial. Simultaneously, there is a noticeable shift towards biologic combination therapies for refractory gout, specifically targeting the severe patient segment unresponsive to conventional oral medications. This trend involves integrating recombinant uricase enzymes with immunomodulatory technologies to mitigate anti-drug antibody formation and sustain therapeutic potency. These advanced regimens are crucial for rapidly reducing crystal deposits in chronic cases, thereby preventing irreversible joint damage. According to Pharmacy Times in January 2025, the novel combination therapy SEL-212 demonstrated a 56% response rate in maintaining serum urate levels below 6 mg/dL in high-dose cohorts, validating its potential to address significant unmet needs in the refractory setting.

Key Market Players

• Takeda Pharmaceutical Company Limited
• AstraZeneca plc
• Horizon Therapeutics plc
• Novartis AG
• Sanofi S.A.
• Teijin Pharma Limited
• Mylan N.V.
• Hikma Pharmaceuticals PLC
• Dr. Reddy's Laboratories Ltd.
• Sun Pharmaceutical Industries Ltd

Report Scope

In this report, the Global Hyperuricemia Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Hyperuricemia Market, by Type:

• Primary
• Secondary

Hyperuricemia Market, by Drug Type:

• Xanthine Oxidase Inhibitors
• Nonsteroidal Anti-Inflammatory Drugs
• Corticosteroids
• Others

Hyperuricemia Market, by Route of Administration:

• Oral
• Injectable

Hyperuricemia Market, by Distribution Channel:

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Hyperuricemia Market, by Region:

• North America
• Europe
• Asia Pacific
• South America
• Middle East & Africa

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Hyperuricemia Market.

Available Customizations:

With the given market data, the publisher offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

This product will be delivered within 1-3 business days.